GlassScriptPhysician profile
Sara Hanna
NPI 1497986368
$1,115.50
in general payments reported to CMS, 2019-2025
21 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.74 · 2020: $47.19 · 2022: $214 · 2023: $133 · 2024: $244 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $227.67 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $171.04 | 2020-2024 | Farxiga |
| Paratek Pharmaceuticals, INC. | $163.09 | 2022-2025 | Nuzyra, Xhance |
| Amgen INC. | $93.46 | 2024-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.11 | 2023-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $59.57 | 2024-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $55.10 | 2020-2025 | Ebglyss |
| Glaxosmithkline, LLC. | $34.23 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $31.52 | 2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $25.03 | 2025 | Ibsrela |
| Horizon Therapeutics Plc | $24.47 | 2022 | |
| Pfizer INC. | $20.74 | 2019 | |
| Merck Sharp & Dohme LLC | $19.19 | 2023 | Belsomra, Steglatro |
| Dexcom, INC. | $17.75 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $17.73 | 2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.29 | 2020 | |
| Seqirus USA INC | $14.69 | 2024 | Flucelvax, Fluad |
| Abbvie INC. | $14.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.43 | 2023 | Jardiance |
| Nevro Corp. | $14.00 | 2024 | Senza |
| Currax Pharmaceuticals LLC | $13.94 | 2025 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Hanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.